EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access

Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine

Stephanie E Kirk, Christina Young, Hayley Berry, Rochelle Hanson, Angela Moreland, Virginia Fonner, Mulugeta Gebregziabher, Jamila Williams, Eric G Meissner iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae472 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Stephanie E Kirk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The need for frequent travel to a clinic could impair access to injectable antiretroviral therapy for persons with human immunodeficiency virus type 1 (HIV-1) infection. We hypothesized that allowing persons receiving treatment with long-acting injectable cabotegravir plus rilpivirine (LA CAB/RPV) to receive and store the medication in their own refrigerator prior to in-home administration by a healthcare provider would be as safe and effective as receiving treatment in a clinic.

Methods

Persons prescribed LA CAB/RPV in the Infectious Diseases clinic at the Medical University of South Carolina were offered enrollment in this non-randomized, observational study between August 2021 and December 2022. After in-clinic receipt of the initial LA CAB/RPV injection, participants chose to receive each subsequent injection over the following 12-months either in clinic or at home.

Results

The 33 enrolled participants were primarily Black (64%), male (73%), and had a median age of 46. Three participants stopped LA CAB/RPV and transitioned to oral antiretroviral therapy due to allergy (n = 1), loss of virologic suppression (n = 1), and visit adherence (n = 1) concerns. A comparable number of participants received treatment primarily in clinic (n = 18) relative to at home (n = 15). Injection site pain/soreness was common (52% of injections) but did not differ between groups. There were no differences in safety or efficacy between groups and both groups reported high treatment satisfaction. All participants were virologically suppressed and retained in care at the end of the study.

Conclusions

At-home administration of LA CAB/RPV by a healthcare provider was comparably safe, effective, and associated with high participant satisfaction relative to in-clinic administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRilpivirineAnti-HIV AgentsPyridonesHumansMaleFemaleMiddle AgedAdultHIV-1Ambulatory Care FacilitiesInjectionsDiketopiperazines

Stichwörter der Autor:innen

HIVcabotegravir/rilpivirine long-actinghome healthlong acting injectable antiretroviralsobservational research study

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Global Health and Population Research, FHI 360, Durham, North Carolina, USA.
  • Department of Public Health Sciences, Health Equity and Rural Outreach Innovation Center (HEROIC), Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.
  • Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Eric G Meissner

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • HRSA HHS
  • ViiV Healthcare
  • Health Resources and Services Administration
  • U.S. Department of Health and Human Services

Zitieren

APA

Kirk, S. E., Young, C., Berry, H., Hanson, R., Moreland, A., Fonner, V., Gebregziabher, M., Williams, J., & Meissner, E. G. (2025). Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae472

Vancouver

Kirk SE, Young C, Berry H, Hanson R, Moreland A, Fonner V, et al. Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae472

BibTeX
@article{Kirk2025,
  author = {Kirk, Stephanie E and Young, Christina and Berry, Hayley and Hanson, Rochelle and Moreland, Angela and Fonner, Virginia and Gebregziabher, Mulugeta and Williams, Jamila and Meissner, Eric G},
  title = {Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae472}
}
Kostenlos starten →